Univ De Stat De Medicin & Abreve & Scedil I Farmacie Nicolae Testemi & Tcedil Anu Din Republica Mold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nicolae Testemitanu, Univ De Stat De Medicin & Abreve & Scedil I Farmacie Nicolae Testemi & Tcedil Anu Din Republica MoldfiledCriticalUniv Nicolae Testemitanu
Priority to MDS20110122ApriorityCriticalpatent/MD501Z/en
Publication of MD501YpublicationCriticalpatent/MD501Y/en
Publication of MD501ZpublicationCriticalpatent/MD501Z/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The invention relates to medicine, namely to radiotherapeutic treatment in oncology.The invention consists in that once a day, immediately after meals, during 15 days from the start of the course of radiotherapy is administered intramuscularly 5 ml of 5% solution of ascorbic acid and perorally one capsule (33000 IU) of retinol, one capsule (0.2 g) of tocopherol and one tablet (0.2 g) of methyluracil. Concomitantly is administered perorally nut kernel oil, one tablespoon (15 ml) twice a day, starting 2…3 days before the start of the course of radiotherapy and then along its entire length.The result is a decrease in the local and general postradiation complications in oncologic patients.
MDS20110122A2011-06-302011-06-30Method for prophylaxis of postradiation complications in oncologic diseases
MD501Z
(en)
Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug